Key Takeaways Regeneron shares have jumped 21.5% YTD on positive pipeline and regulatory updates.Eylea HD approvals and rising demand help counter pressure from competing ophthalmology therapies.Label expansions for Libtayo and strong Dupixent sales continue to support Regeneron's top-line growth.Shares of Regeneron Pharmaceuticals (REGN) have gained 21.5% year to date compared with the industry’s growth of 10.2%. The stock has also outperformed the sector and the S&P 500 Index during this time frame.The ra ...